Therapeutic efficacy of low‐dose (25\u2009mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases

Abstract

The incidence of overactive bladder (OAB) increases with age, especially in patients with central nervous system (CNS) disorders such as cerebrovascular accident (CVA) and Parkinson s disease (PD). Mirabegron is a novel medication for the treatment of OAB. The present study investigated the therapeutic effect of mirabegron on OAB patients with CNS diseases.